High‐Dose Amphotericin B with Flucytosine for the Treatment of Cryptococcal Meningitis in HIV‐Infected Patients: A Randomized Trial | Zendy

Tihana Bicanic | Zendy; Robin Wood | Zendy; Graeme Meintjes | Zendy; Kevin Rebe | Zendy; Annemarie E. Brouwer | Zendy; Angela Loyse | Zendy; LindaGail Bekker | Zendy; Shabbar Jaffar | Zendy; Thomas S. Harrison | Zendy

Open Access

High‐Dose Amphotericin B with Flucytosine for the Treatment of Cryptococcal Meningitis in HIV‐Infected Patients: A Randomized Trial

Author(s) -

Tihana Bicanic,

Robin Wood,

Graeme Meintjes,

Kevin Rebe,

Annemarie E. Brouwer,

Angela Loyse,

LindaGail Bekker,

Shabbar Jaffar,

Thomas S. Harrison

Publication year - 2008

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/588792

Subject(s) - flucytosine , medicine , amphotericin b , fluconazole , meningitis , randomized controlled trial , cryptococcosis , gastroenterology , surgery , immunology , antifungal , dermatology

The standard therapy for human immunodeficiency virus (HIV)-associated cryptococcal meningitis of amphotericin B (AmB; 0.7 mg/kg per day) plus flucytosine frequently takes >2 weeks to sterilize the cerebral spinal fluid, and acute mortality remains high. A dosage range for AmB of 0.7-1 mg/kg per day is noted in current guidelines, but there are no data comparing 0.7 mg/kg per day with 1 mg/kg per day.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research